🚨🚨🚨📣📣📣yes, you read correctly, changes to 1st line therapy in #T2DM - patient specific factors for the win 🙌🏻 Metformin is still great! But think of #SLGT2 and #GLP1 for patients with compelling indications. Coverage will be main barrier IMO #twitterx#medtwitter#ambcarerx
Now for the #HFSA2021 session I am most excited for: Implementing GDMT In Severe Heart Failure Patients - Easy or Challenging? A Debate between @nancy_m_albert and @gcfmd
Initial poll suggests most audience members feel implementation of GDMT in advanced HF is challenging
https://t.co/hXVzG2p9oq
1/
Congratulations to the EMPEROR-Preserved Trial Investigators and participants on this landmark trial.
Here are my top 10 observations:
1. Excellent trial conduct with vital status missing in only 0.6%
It is important to note the majority use of clopidgrel, the specific stent, and assuring patients are free of events before stopping. Great trial! @ACCinTouch#ACCCVT@accpcardprn
Heart failure with reduced ejection fraction complicates the management of comorbidities, including varying safety & efficacy of therapies compared to those without HF. https://t.co/wtCilSILZN @ATRIUMRx @stormigale@brentreed@bamardis @michael_plazak @alinakukin@accpcardprn
Patient prescribed home milrinone by outpatient MD admitted for cardiogenic shock. Optimized hemodynamics with NTP/transition to GDMT. Now discharging stable OFF milrinone on BB, ARNI, AA, and SGLT2i. Friendly reminder that #GDMTworks and to refer to a advanced HF specialist!
Perhaps there is some merit to improvement in GI ulceration with this formulation. But the incidence of erosions/ulcerations seems awfully high in this study. Thoughts? https://t.co/6PyjWlrzS1
New ASA formulation- liquid filled capsule- FDA approved and shown to have quicker time to platelet inhibition... compared to ENTERIC coated ASA. Would have liked to see chewable ASA as comparator. https://t.co/s4BeXjQnpE